AUGUSTI, Mark
To:Integra LifeSciences Holdings Corp., Corp. VP, Orthopedics & Tissue Technologies (April)
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
AUGUSTI, Mark
To:Integra LifeSciences Holdings Corp., Corp. VP, Orthopedics & Tissue Technologies (April)
In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.
The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.
For the full year, the company now expects tariffs to increase the cost of sales by approximately 1% of revenue, plus or minus 20 basis points. This is lower than the previous estimate of approximately 1.7% of revenue. The updated gross margin guidance for 2025 is 66%-67%, up from 65%-66.5%.